NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Odyssey Therapeutics, Inc. (ODTX) Stock Analysis

Odyssey Therapeutics, Inc. (ODTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ODTX

$19.00

+$0.01 (+0.05%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ODTX with… →

ODTX Key Statistics

As of Oct 21, 2026
Trading
Open
$18.93
Previous Close
$18.99
Day's Range
18.00–19.79
52-Week Range
15.10–29.05
Volume
255.34K
Valuation
Market Cap
$913.11M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9,223.35
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.55
Financials (FY)
Revenue (FY)
$2.98M−33.45%
Net Income (FY)
−$148.65M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.06M
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
257.09K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Odyssey Therapeutics, Inc. (ODTX) has a market capitalization of $913.11M.

In fiscal 2025, ODTX reported revenue of $2.98M.

ODTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.98M−$148.65M−4,994.9%
2024$4.47M−$129.32M−2,891.8%
2023$1.04M−$125.94M−12,144.5%
2022$0.00−$124.67M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.98M—−$161.16M−$148.65M−4,994.9%
2024$4.47M—−$135.22M−$129.32M−2,891.8%
2023$1.04M—−$133.44M−$125.94M−12,144.5%
2022$0.00—−$122.78M−$124.67M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Odyssey Therapeutics, Inc. (ODTX) at $913.11M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 100.

Over the past 52 weeks the price has ranged from $15.10 to $29.05. The most recent close on file for ODTX is $19.00, dated October 21, 2026. That is +$0.01 (+0.05%) against the previous close. The latest close sits 25.83% above that 52-week low.

Financial Health

In fiscal 2025, Odyssey Therapeutics, Inc. reported revenue of $2.98M. Against the prior fiscal year total of $4.47M, that is a change of −33.45%. The same year closed with a net loss of $148.65M. Trailing earnings per share are −7.55.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $2.98M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 9,223.35 times revenue. On price-to-sales that is 693.6 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Growth & Income

The record shows no dividend for ODTX.

So far in 2026 the total return is +15.71%.

Peer Comparison

Odyssey Therapeutics, Inc. (ODTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Odyssey Therapeutics, Inc. ODTX $913.11M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Odyssey Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

Visit website →